Baseline characteristics of the 177 RA patients according to FCGR3A genotype
| 158VV (n=18) | 158VF (n=78) | 158FF (n=81) | Total (n=177) | |
|---|---|---|---|---|
| Mean (SD) disease duration, years | 11 (6) | 15 (10) | 14 (12) | 14 (11) |
| Females, n (%) | 13 (72) | 61 (78) | 71 (88) | 145 (82) |
| Rheumatoid factor positive, n (%) | 12 (67) | 62 (81) | 63 (78) | 137 (78) |
| Baseline DAS28, mean (SD) | 5.2 (1.0) | 5.5 (1.1) | 5.5 (1.2) | 5.5 (1.1) |
| Concurrent DMARD therapy, n (%) | 15 (83) | 48 (62) | 59 (73) | 122 (69) |
| Oral glucocorticoid therapy, n (%)* | 13 (72) | 55 (72)# | 48 (64)## | 116 (69)### |
| Number of previous TNF inhibitors, mean (SD) | 1.4 (1.2) | 1.3 (1.1) | 1.2 (1.1) | 1.3 (1.1) |
*Data available on: #76/78 patients, ##75/81 patients, ###169/177 patients.
DMARD, disease modifying antirheumatic drugs; TNF, tumour necrosis factor.